Alberto Boccalini
YOU?
Author Swipe
View article: No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐<scp>CGRP</scp> Monoclonal Antibodies: A Prospective Observational Study (<scp>SAFHYPER</scp>)
No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐<span>CGRP</span> Monoclonal Antibodies: A Prospective Observational Study (<span>SAFHYPER</span>) Open
Background Migraine is associated with an increased cardiovascular risk, including hypertension. Anti‐calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised ab…
View article: Safety of Onabotulinumtoxin-A for Chronic Migraine During Pregnancy and Breastfeeding: A Narrative Review
Safety of Onabotulinumtoxin-A for Chronic Migraine During Pregnancy and Breastfeeding: A Narrative Review Open
Onabotulinumtoxin-A (onabotA) is a neurotoxin widely used for several indications, including chronic migraine (CM) preventive treatment, due to its well-demonstrated efficacy, tolerability, and safety. However, onabotA safety during pregna…
View article: Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study Open
Background The anti-calcitonin gene-related peptide (CGRP), or its receptor (CGRP/R) monoclonal antibodies (mAbs), offer targeted, effective, and tolerated drugs for migraine. However, about 25% of patients fail to achieve a clinically mea…
View article: Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations
Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations Open
Background: Small molecule receptor antagonists (gepants), or monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) have recently become available for migraine prophylaxis and/or acute treatment. Considering their sha…
View article: Building the Momentum for A Stronger Pharmaceutical System in Africa
Building the Momentum for A Stronger Pharmaceutical System in Africa Open
Despite impressive progress, nearly two billion people worldwide have no access to essential medicines. The COVID-19 pandemic revealed Africa’s vulnerability due to its reliance on imports for most vaccines, medicines, and other health pro…